

Supplemental Figures

Figure S1:

- (a) Venn diagram to represent overlap between hnRNP M-regulated transcripts in uninfected and *Salmonella*-infected macrophages.
- (b) Complete ingenuity pathway analysis for SCR vs. hnRNP M KD uninfected macrophages
- (c) Complete ingenuity pathway analysis for SCR vs. hnRNP M KD *Salmonella*-infected macrophages
- (d) Additional validation of RNA-seq results. Gene expression by RT-qPCR in SCR, hnRNP M KD 1, and hnRNP M KD 2 2h post-*Salmonella* infection for *Adora2a*, *Marcks*, *Mx1*, *Gbp5*, and 4h for *Adora2a* and *Marcks*.

Figure S2:

- (a) Additional gene expression by RT-qPCR in LPS-treated cells, SCR, hnRNP M KD 1, and hnRNP M KD 2h post-treatment. *Tnfa*, *Marcks*, and *Gbp5*.
- (b) *IL6* expression by RT-qPCR in SCR, hnRNP M KD1, and hnRNP M KD 2 8h post-LPS treatment.

Figure S3:

- (a) Venn diagram to represent overlap between hnRNP M-regulated transcripts identified via RNA-SEQ analysis (unique genes identified in *Salmonella* and uninfected analyses) and hnRNP M-dependent LSVs identified via MAJIQ analysis (total number of unique LSV events from both *Salmonella* and uninfected conditions).
- (b) Full VOILA-generated tracks for *Commd8* and *Nmt2*. Significant LSVs are shown in color.

Figure S4:

- (a) Immunofluorescence microscopy of 3xFLAG-hnRNP M in untreated and LPS-treated macrophages (1h and 2h post-treatment)
- (b) Immunofluorescence microscopy of hnRNP U in untreated and LPS-treated macrophages (2h post-treatment)
- (c) Western blot of whole cell lysate, cytoplasm, nucleoplasm, and chromatin of fractionated stable 3xFL-hnRNP M-expressing macrophages over a time-course of LPS treatment.
- (d) RNA sequence of *IL6* introns 2 and 3. Consensus or near-consensus hnRNP M binding sites are highlighted in yellow.

Figure S5:

- (a) Western blot analysis of hnRNP M phosphomutants stably expressed in RAW 264.7 macrophages
- (b) *IL6* expression by RT-qPCR, 2h post-LPS treatment in 3xFL-hnRNP M WT and 3xFL-hnRNP M S587A/D-expressing macrophages
- (c) *Mx1* expression, 2h post-LPS treatment in 3xFL-hnRNP M WT and 3xFL-hnRNP M S587A/D-expressing macrophages
- (d) Expression by RT-qPCR of *Rnf26*, *Slc6a4*, *Rnf128* for 3xFL-hnRNP M WT, hnRNP M KD 1 and 2, and 3xFL-S431A/D, S574A/D, S85A/D, S480A/D-expressing cells
- (e) Western blot of whole cell lysate and chromatin of fractionated stable 3xFL-hnRNP M WT, 3xFL-hnRNP M 431A/D and 3xFL-hnRNP M 574A/D-expressing cell lines.


Figure S6:

- (a) RT-qPCR of *Ifn β* mRNA levels in SCR control and hnRNP M KD cells at 2h and 4h post-infection, MOI=0.1. (b) RT-qPCR of *Mx1* transcript in VSV infected SCR control and hnRNP M KD cells at 2h, 4h, and 8h post-infection, MOI=0.1. (c) RT-qPCR of *IL6* transcript in SCR control and hnRNP M KD cells at 2h, 4h, and 8h post-infection MOI=0.1. All figures are representative of 2 biological replicates.

Figure S7:


- (a) Screenshots of IGV viewer of *Salmonella*-infected SCR- and hnRNP M KD RNA-SEQ reads at *Fcgr3*, *Cd276*, *Nfkbiz*, *Tnfaip3*, *Mir6989*. Red arrows indicate potential cryptic exons.

a

SCR vs. hnRNP M KD1 Uninfected SCR vs. hnRNP M KD1 + *Salmonella*


b

Canonical Pathway Analysis: SCR vs. hnRNP M KD1 Uninfected




c



Canonical Pathway Analysis: SCR vs. hnRNP M KD1 +STm




d



a




a




b

Gene ID: *Commd8*

SCR




hnRNP M KD





Gene ID: *Nmt2*


SCR




hnRNP M KD









Fcgr3




Cd276



Nfkbiz



Tnfaip3



Mir6989

